Liquidia Corp (LQDA): Total Assets
$327.93M
As of 2025-12-31
$521.92M
As of 2026-06-30
+36.4%
3-year compound annual growth
+26.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $327.93M | +42.4% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $230.31M | +94.6% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $118.33M | -8.4% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $129.20M | +37.8% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $93.73M | -5.8% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $99.53M | +44.6% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $68.84M | n/a | 2021-03-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Liquidia Corp (LQDA) | 2025-12-31 | $327.93M | +42.4% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $255.88M | +9.7% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $256.85M | -1.8% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $138.29M | +43.5% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $108.42M | -34.1% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $259.15M | -31.5% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $764.99M | +8.7% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $62.11M | -13.7% |
Compare LQDA, HRTX, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗